PANTO-BYK TABLET (ENTERIC-COATED)

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM)

Saatavilla:

NYCOMED GMBH

ATC-koodi:

A02BC02

INN (Kansainvälinen yleisnimi):

PANTOPRAZOLE

Annos:

40MG

Lääkemuoto:

TABLET (ENTERIC-COATED)

Koostumus:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM) 40MG

Antoreitti:

ORAL

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

PROTON-PUMP INHIBITORS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0133229001; AHFS:

Valtuutuksen tilan:

CANCELLED PRE MARKET

Valtuutus päivämäärä:

2017-07-13

Valmisteyhteenveto

_PANTO-BYK (pantoprazole sodium) _
_ _
_ _
_Page 1 of 37 _
PRODUCT MONOGRAPH
PR PANTO-BYK
pantoprazole sodium enteric-coated tablets
(as pantoprazole 20, 40 mg)
H+, K+-ATPase Inhibitor
Nycomed GmbH
Byk-Gulden Strasse 2
78467 Konstanz, Germany
Distributor:
Takeda Canada Inc.
435 North Service Road West, 1st Floor
Oakville, ON L6M 4X8
Date of Revision:
February 21, 2013
SUBMISSION CONTROL NO: 161771
_PANTO-BYK (pantoprazole sodium) _
_ _
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY
PRODUCT
INFORMATION
...........................................................................
3
INDICATIONS
AND
CLINICAL
USE
.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
4
WARNINGS
AND
PRECAUTIONS.....................................................................................
4
ADVERSE
REACTIONS
......................................................................................................
7
DRUG
INTERACTIONS
.....................................................................................................
11
DOSAGE
AND
ADMINISTRATION
.................................................................................
13
OVERDOSE
.........................................................................................................................
14
ACTION
AND
CLINICAL
PHARMACOLOGY
............................................................... 14
STORAGE
AND
STABILITY
............................................................................................
16
SPECIAL
HANDLING
INSTRUCTIONS
..........................................................................
16
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ................................................ 17
PART II: SCIENTIFIC INFORMATION
.........................................................................
18
PHA